Monopar Therapeutics (NASDAQ:MNPR) Price Target Raised to $22.00 at HC Wainwright

Monopar Therapeutics (NASDAQ:MNPR) had its price objective hoisted by HC Wainwright from $6.00 to $22.00 in a report published on Monday morning,Benzinga reports. The firm currently has a buy rating on the stock.

Separately, Rodman & Renshaw assumed coverage on Monopar Therapeutics in a report on Friday, October 11th. They set a “buy” rating and a $50.00 target price on the stock.

Monopar Therapeutics Price Performance

MNPR traded down $0.17 during trading on Monday, reaching $16.49. 2,871 shares of the stock were exchanged, compared to its average volume of 691,569. Monopar Therapeutics has a 1 year low of $1.37 and a 1 year high of $38.50. The company has a market capitalization of $65.30 million, a price-to-earnings ratio of -8.46 and a beta of 1.09. The business’s 50 day moving average price is $7.84 and its two-hundred day moving average price is $4.91.

Monopar Therapeutics (NASDAQ:MNPR) last issued its quarterly earnings data on Friday, November 8th. The company reported ($0.37) EPS for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.09. On average, analysts anticipate that Monopar Therapeutics will post -1.93 EPS for the current year.

Insider Buying and Selling

In other Monopar Therapeutics news, CFO Karthik Radhakrishnan bought 1,550 shares of Monopar Therapeutics stock in a transaction that occurred on Monday, October 28th. The shares were purchased at an average cost of $16.25 per share, for a total transaction of $25,187.50. Following the completion of the transaction, the chief financial officer now owns 1,550 shares of the company’s stock, valued at $25,187.50. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 34.90% of the stock is owned by company insiders.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.